Eli Lilly & Co. , already facing competition next year for its top-selling drug, lost a court bid over patent protection on its cancer medicine Gemzar , which could lead to generic products as early as November.
Hospira Inc., the maker of generic injectable drugs, gained the most in almost five months after the company said a factory cited for manufacturing deficiencies had reopened and was near previous production levels.
Cubist Pharmaceuticals Inc., a maker of antibiotic medicines, sued Hospira Inc. for patent infringement over plans to market a generic version of Cubicin, a drug used to combat the MRSA flesh-eating bacterium.
Eli Lilly & Co. ’s patent- infringement claim over Hospira Inc. ’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
Eli Lilly & Co. , already facing competition next year for its top-selling drug, lost a bid to block generic sales of the cancer medicine Gemzar after November, opening the door to rivals two years earlier than the company anticipated.